Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839

Current Opinion in Chemical Biology

Volumn 12, Issue 4, 2008, Pages 409-417

  Critchley, Ian A ^a   Ochsner, Urs A ^a  

^a Replidyne Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFALEXIN; DIAMINE; FLUOROVINYLTHIOPHENE; FUSIDIC ACID; METHIONINE TRANSFER RNA LIGASE; PSEUDOMONIC ACID; REP 8839; RETAPAMULIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; MONOTHERAPY; NONHUMAN; PHENOTYPE; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; WOUND INFECTION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; DIAMINES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; HUMANS; METHIONINE-TRNA LIGASE; THIOPHENES;

BACTERIA (MICROORGANISMS); POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; SUS;

EID: 50449097572     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2008.06.011     Document Type: Review

References (46)

1. Kluytmans-Vandenbergh M.F., and Kluytmans J.A. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infect 12 Suppl 1 (2006) 9-15. A recent review of the epidemiology of MRSA in different countries.
2. Tristan A., Bes M., Meugnier H., Lina G., Bozdogan B., Courvalin P., Reverdy M.E., Enright M.C., Vandenesch F., and Etienne J. Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis 13 (2007) 594-600. Provides an overview of some of the molecular typing methods commonly used to characterize MRSA isolates.
3. Simor A.E., Stuart T.L., Louie L., Watt C., Ofner-Agostini M., Gravel D., Mulvey M., Loeb M., McGeer A., Bryce E., and Matlow A. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 51 (2007) 3880-3886. Describes the epidemiology and clinical features of hospitalized patients with high-level mupirocin MRSA in a network of Canadian hospitals between 1995 and 2004. The article describes how these isolates were characterized, their molecular epidemiology, and mechanism of mupirocin resistance.
4. Fujimura S., Tokue Y., and Watanabe A. Isoleucyl-tRNA synthetase mutations in Staphylococcus aureus clinical isolates and in vitro selection of low-level mupirocin-resistant strains. Antimicrob Agents Chemother 47 (2003) 3373-3374
5. Udo E.E., Al-Sweih N., and Noronha B.C. A chromosomal location of the mupA gene in Staphylococcus aureus expressing high-level mupirocin resistance. J Antimicrob Chemother 51 (2003) 1283-1286
6. Simor A.E., Phillips E., McGeer A., Konvalinka A., Loeb M., Devlin H.R., and Kiss A. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 44 (2007) 178-185
7. Walker E.S., Vasquez J.E., Dula R., Bullock H., and Sarubbi F.A. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective?. Infect Control Hosp Epidemiol 24 (2003) 342-346
8. Laurberg M., Kristensen O., Martemyanov K., Gudkov A.T., Nagaev I., Hughes D., and Liljas A. Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site. J Mol Biol 303 (2000) 593-603
9. O'Neill A.J., Larsen A.R., Skov R., Henriksen A.S., and Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol 45 (2007) 1505-1510
10. O'Neill A.J., and Chopra I. Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus. Mol Microbiol 59 (2006) 664-676
11. Daum R.S., Kar S., and Kirkpatrick P. Retapamulin. Nat Rev Drug Discov 6 (2007) 865-866
12. Jacobs M.R. Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children. Future Microbiol 2 (2007) 591-600. A recent review of the key preclinical and clinical properties of retapamulin, a new topical antibiotics recently launched in the USA and Europe by GlaxoSmithKline.
13. Laustsen G., Shaul M., and Short G. Retapamulin (altabax). Nurse Pract 33 (2008) 15
14. Champney W.S., and Rodgers W.K. Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother 51 (2007) 3385-3387
15. Yan K., Madden L., Choudhry A.E., Voigt C.S., Copeland R.A., and Gontarek R.R. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother 50 (2006) 3875-3881
16. Cada D.J., Levien T., and Baker D.E. Retapamulin 1% ointment. Hosp Pharm 42 (2007) 846-855
17. Critchley I.A., Young C.L., Stone K.C., Ochsner U.A., Guiles J., Tarasow T., and Janjic N. Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother 49 (2005) 4247-4252. This study describes the initial microbiological profile of REP8839 including its activity against key phenotypes of S. aureus.
18. Bharatham N., Bharatham K., and Lee K.W. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors. J Mol Graph Model 25 (2007) 813-823
19. Farhanullah, Kim S.Y., Yoon E.J., Choi E.C., Kim S., Kang T., Samrin F., Puri S., and Lee J. Design and synthesis of quinolinones as methionyl-tRNA synthetase inhibitors. Bioorg Med Chem 14 (2006) 7154-7159
20. Hurdle J.G., O'Neill A.J., and Chopra I. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother 49 (2005) 4821-4833
21. Kedar G.C., Brown-Driver V., Reyes D.R., Hilgers M.T., Stidham M.A., Shaw K.J., Finn J., and Haselbeck R.J. Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis. Antimicrob Agents Chemother 51 (2007) 1708-1718
22. Ochsner U.A., Sun X., Jarvis T., Critchley I., and Janjic N. Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents. Expert Opin Investig Drugs 16 (2007) 573-593. A comprehensive review of amino acyl tRNA synthetases, including MetRS, and their suitability as novel targets for antibiotic development.
23. Tandon M., Coffen D.L., Gallant P., Keith D., and Ashwell M.A. Potent and selective inhibitors of bacterial methionyl tRNA synthetase derived from an oxazolone-dipeptide scaffold. Bioorg Med Chem Lett 14 (2004) 1909-1911
24. Cole C., and Gazewood J. Diagnosis and treatment of impetigo. Am Fam Phys 75 (2007) 859-864. A recent review is describing the clinical properties of impetigo as a superficial skin infection and the use of topical and systemic agents to treat these infections.
25. Koning S., van der Wouden J.C., Chosidow O., Twynholm M., Singh K.P., Scangarella N., and Oranje A.P. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol 158 (2008) 1077-1082. This study describes the results from a Phase III clinical trial to evaluate the safety and efficacy of topical retapamulin in treating impetigo.
26. Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis 21 (2008) 122-128. A review describes common bacterial skin infections, pathogens, and current treatment strategies.
27. Patel M., Waites K.B., Hoesley C.J., Stamm A.M., Canupp K.C., and Moser S.A. Emergence of USA300 MRSA in a tertiary medical centre: implications for epidemiological studies. J Hosp Infect 68 (2008) 208-213
28. Skiest D.J., and Cooper T.W. High recurrence rate of CA-MRSA skin and soft tissue infections. Arch Intern Med 167 (2007) 2527 author
29. Jarvest R.L., Berge J.M., Berry V., Boyd H.F., Brown M.J., Elder J.S., Forrest A.K., Fosberry A.P., Gentry D.R., Hibbs M.J., et al. Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. J Med Chem 45 (2002) 1959-1962. Of significance because it was the first study describing inhibitors of S. aureus MetRS and their potential as novel antibacterial agents.
30. Jarvest R.L., Berge J.M., Brown M.J., Brown P., Elder J.S., Forrest A.K., Houge-Frydrych C.S., O'Hanlon P.J., McNair D.J., Rittenhouse S., and Sheppard R.J. Optimisation of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent gram-positive antibacterial activity. Bioorg Med Chem Lett 13 (2003) 665-668
31. Jarvest R.L., Berge J.M., Brown P., Houge-Frydrych C.S., O'Hanlon P.J., McNair D.J., Pope A.J., and Rittenhouse S. Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-positive antibacterial activity. Bioorg Med Chem Lett 13 (2003) 1265-1268
32. Jarvest R.L., Armstrong S.A., Berge J.M., Brown P., Elder J.S., Brown M.J., Copley R.C., Forrest A.K., Hamprecht D.W., O'Hanlon P.J., et al. Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues. Bioorg Med Chem Lett 14 (2004) 3937-3941
33. Brown J.R., Gentry D., Becker J.A., Ingraham K., Holmes D.J., and Stanhope M.J. Horizontal transfer of drug-resistant aminoacyl-transfer-RNA synthetases of anthrax and Gram-positive pathogens. EMBO Rep 4 (2003) 692-698. Provides a phylogenetic analysis of MetRS among different bacteria.
34. Bernier S., Akochy P.M., Lapointe J., and Chenevert R. Synthesis and aminoacyl-tRNA synthetase inhibitory activity of aspartyl adenylate analogs. Bioorg Med Chem 13 (2005) 69-75
35. Shen N., Guo L., Yang B., Jin Y., and Ding J. Structure of human tryptophanyl-tRNA synthetase in complex with tRNATrp reveals the molecular basis of tRNA recognition and specificity. Nucleic Acids Res 34 (2006) 3246-3258
36. Gentry D.R., Ingraham K.A., Stanhope M.J., Rittenhouse S., Jarvest R.L., O'Hanlon P.J., Brown J.R., and Holmes D.J. Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes. Antimicrob Agents Chemother 47 (2003) 1784-1789. This is the first report to describe a divergent metRS2 enzyme in S. pneumoniae.
37. Laursen B.S., Sorensen H.P., Mortensen K.K., and Sperling-Petersen H.U. Initiation of protein synthesis in bacteria. Microbiol Mol Biol Rev 69 (2005) 101-123
38. Ochsner U.A., Young C.L., Stone K.C., Dean F.B., Janjic N., and Critchley I.A. Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase. Antimicrob Agents Chemother 49 (2005) 4253-4262. This is the first report describing the biochemical and microbiological mode of action of REP8839 confirming metRS as the target.
39. Richter S.S., Heilmann K.P., Beekmann S.E., Miller N.J., Miller A.L., Rice C.L., Doern C.D., Reid S.D., and Doern G.V. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 41 (2005) 599-608
40. Drago L., De V.E., Nicola L., and Gismondo M.R. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect Dis 7 (2007) 111
41. Dumitrescu O., Badiou C., Bes M., Reverdy M.E., Vandenesch F., Etienne J., and Lina G. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 14 (2008) 384-388
42. Manresa H., and Meyers A.D. Combination products and the FDA: issues and answers. Biotechnol Healthc (2005) 41-44
43. Gisby J., and Bryant J. Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother 44 (2000) 255-260
44. Rittenhouse S., Singley C., Hoover J., Page R., and Payne D. Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic. Antimicrob Agents Chemother 50 (2006) 3886-3888
45. Davis S.C., Ricotti C., Cazzaniga A., Welsh E., Eaglstein W.H., and Mertz P.M. Microscopic and physiologic evidence for biofilm-associated wound colonization in vivo. Wound Repair Regen 16 (2008) 23-29. Provides additional information on the porcine partial thickness wound model, the differences between colonizing organisms and established biofilms and their susceptibility to topical antimicrobial.
46. Pope A.J., McVey M., Fantom K., and Moore K.J. Effects of substrate and inhibitor binding on proteolysis of isoleucyl-tRNA synthetase from Staphylococcus aureus. J Biol Chem 273 (1998) 31702-31706